The efficacy of Zafirlukast as a SARS-CoV-2 helicase inhibitor in adult patients with moderate COVID-19 Pneumonia (pilot randomized clinical trial)

The efficacy of Zafirlukast as a SARS-CoV-2 helicase inhibitor in adult patients with moderate COVID-19 Pneumonia (pilot randomized clinical trial)

Objective: To assess the efficacy of Zafirlukast as a SARS-CoV-2 Helicase Inhibitor in adult patients with moderate COVID-19 symptoms (hospitalized patients with COVID-19 pneumonia who were not admitted to an intensive care unit). Methods: We conducted a randomized, double blind, placebo-controlled,...

Full description

Bibliographic Details
Main Authors: M.Al Ghobain, F. Rebh, A. Saad, A.H. Khan, N. Mehyar, A. Mashhour, I. Islam, Y. Alobaida, A.S. Alaskar, M. Boudjelal, M.Al Jeraisy
Format: Article
Language:English
Published: Elsevier 2022-12-01
Series:Journal of Infection and Public Health
Subjects:
COVID-19
Coronavirus
Zafirlukast
Randomized clinical trial
SARS-CoV-2
Online Access:http://www.sciencedirect.com/science/article/pii/S1876034122003094

Internet

http://www.sciencedirect.com/science/article/pii/S1876034122003094

Similar Items